Skip to main content
Top
Published in: Osteoporosis International 7/2021

Open Access 01-07-2021 | Care | Consensus Statement

Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region

Authors: M. Chandran, P. J. Mitchell, T. Amphansap, S. K. Bhadada, M. Chadha, D.-C. Chan, Y.-S. Chung, P. Ebeling, N. Gilchrist, A. Habib Khan, P. Halbout, F. L. Hew, H.-P. T. Lan, T. C. Lau, J. K. Lee, S. Lekamwasam, G. Lyubomirsky, L. B. Mercado-Asis, A. Mithal, T. V. Nguyen, D. Pandey, I. R. Reid, A. Suzuki, T. T. Chit, K. L. Tiu, T. Valleenukul, C. K. Yung, Y. L. Zhao, on behalf of the Asia Pacific Consortium on Osteoporosis (APCO)

Published in: Osteoporosis International | Issue 7/2021

Login to get access

Abstract

Summary

Guidelines for doctors managing osteoporosis in the Asia-Pacific region vary widely. We compared 18 guidelines for similarities and differences in five key areas. We then used a structured consensus process to develop clinical standards of care for the diagnosis and management of osteoporosis and for improving the quality of care.

Purpose

Minimum clinical standards for assessment and management of osteoporosis are needed in the Asia-Pacific (AP) region to inform clinical practice guidelines (CPGs) and to improve osteoporosis care. We present the framework of these clinical standards and describe its development.

Methods

We conducted a structured comparative analysis of existing CPGs in the AP region using a “5IQ” model (identification, investigation, information, intervention, integration, and quality). One-hundred data elements were extracted from each guideline. We then employed a four-round Delphi consensus process to structure the framework, identify key components of guidance, and develop clinical care standards.

Results

Eighteen guidelines were included. The 5IQ analysis demonstrated marked heterogeneity, notably in guidance on risk factors, the use of biochemical markers, self-care information for patients, indications for osteoporosis treatment, use of fracture risk assessment tools, and protocols for monitoring treatment. There was minimal guidance on long-term management plans or on strategies and systems for clinical quality improvement. Twenty-nine APCO members participated in the Delphi process, resulting in consensus on 16 clinical standards, with levels of attainment defined for those on identification and investigation of fragility fractures, vertebral fracture assessment, and inclusion of quality metrics in guidelines.

Conclusion

The 5IQ analysis confirmed previous anecdotal observations of marked heterogeneity of osteoporosis clinical guidelines in the AP region. The Framework provides practical, clear, and feasible recommendations for osteoporosis care and can be adapted for use in other such vastly diverse regions. Implementation of the standards is expected to significantly lessen the global burden of osteoporosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference International Osteoporosis Foundation (2013) The Asia-Pacific regional audit. Epidemiology, costs and burden of osteoporosis in 2013. IOF, Nyon, Switzerland International Osteoporosis Foundation (2013) The Asia-Pacific regional audit. Epidemiology, costs and burden of osteoporosis in 2013. IOF, Nyon, Switzerland
2.
go back to reference World Bank (2016) Live long and prosper: aging in East Asia and Pacific. World Bank, Washington, DCCrossRef World Bank (2016) Live long and prosper: aging in East Asia and Pacific. World Bank, Washington, DCCrossRef
4.
go back to reference United Nations Department of Economic and Social Affairs Population Division (2019) World population ageing 2019. Highlights, United Nations, New York United Nations Department of Economic and Social Affairs Population Division (2019) World population ageing 2019. Highlights, United Nations, New York
6.
go back to reference Chandran M, Bhadada SK, Ebeling PR et al (2020) IQ driving QI: the Asia Pacific Consortium on Osteoporosis (APCO): an innovative and collaborative initiative to improve osteoporosis care in the Asia Pacific. Osteoporos Int 31:2077–2081PubMedPubMedCentralCrossRef Chandran M, Bhadada SK, Ebeling PR et al (2020) IQ driving QI: the Asia Pacific Consortium on Osteoporosis (APCO): an innovative and collaborative initiative to improve osteoporosis care in the Asia Pacific. Osteoporos Int 31:2077–2081PubMedPubMedCentralCrossRef
7.
go back to reference Arai H, Ikeda S, Okuro M et al (2019) Clinical standards for fracture liaison services in Japan. Japan Osteoporosis Society and Fragility Fracture Network Japan, Tokyo Arai H, Ikeda S, Okuro M et al (2019) Clinical standards for fracture liaison services in Japan. Japan Osteoporosis Society and Fragility Fracture Network Japan, Tokyo
8.
go back to reference Osteoporosis New Zealand (2017) Clinical standards for fracture liaison services in New Zealand. Osteoporosis New Zealand, Wellington Osteoporosis New Zealand (2017) Clinical standards for fracture liaison services in New Zealand. Osteoporosis New Zealand, Wellington
9.
go back to reference Gittoes N, McLellan AR, Cooper A et al (2015) Effective secondary prevention of fragility fractures: clinical standards for fracture liaison services. National Osteoporosis Society, Camerton Gittoes N, McLellan AR, Cooper A et al (2015) Effective secondary prevention of fragility fractures: clinical standards for fracture liaison services. National Osteoporosis Society, Camerton
10.
go back to reference Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28:1507–1529PubMedPubMedCentralCrossRef Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28:1507–1529PubMedPubMedCentralCrossRef
11.
go back to reference Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C (2011) Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One 6:e20476PubMedPubMedCentralCrossRef Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C (2011) Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One 6:e20476PubMedPubMedCentralCrossRef
12.
go back to reference The Royal Australian College of General Practitioners, Osteoporosis Australia (2017) Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age, 2nd edn. RACGP, East Melbourne The Royal Australian College of General Practitioners, Osteoporosis Australia (2017) Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age, 2nd edn. RACGP, East Melbourne
13.
go back to reference Osteoporosis and Bone Mineral Disease Branch of Chinese Medical Association (2017) Guidelines for the diagnosis and treatment of primary osteoporosis (2017). Chin J Osteo Bone Miner Res 10:413–444 Osteoporosis and Bone Mineral Disease Branch of Chinese Medical Association (2017) Guidelines for the diagnosis and treatment of primary osteoporosis (2017). Chin J Osteo Bone Miner Res 10:413–444
14.
go back to reference Workgroup of 2018 China Guideline for the Diagnosis and Treatment of Senile Osteoporosis, Osteoporosis Society of China Association of Gerontology and Geriatrics, Ma Y et al (2018) 2018 China guideline for the diagnosis and treatment of senile osteoporosis [in Chinese]. Chin J Health Manage 12:484–509 Workgroup of 2018 China Guideline for the Diagnosis and Treatment of Senile Osteoporosis, Osteoporosis Society of China Association of Gerontology and Geriatrics, Ma Y et al (2018) 2018 China guideline for the diagnosis and treatment of senile osteoporosis [in Chinese]. Chin J Health Manage 12:484–509
15.
go back to reference Osteoporosis Group Orthopaedic Branch Chinese Medical Association, Liu Q, Cao L et al (2017) Guidelines for the diagnosis and treatment of osteoporotic fractures [in Chinese]. Chinese Journal of Orthopaedics 37:1–10 Osteoporosis Group Orthopaedic Branch Chinese Medical Association, Liu Q, Cao L et al (2017) Guidelines for the diagnosis and treatment of osteoporotic fractures [in Chinese]. Chinese Journal of Orthopaedics 37:1–10
16.
go back to reference Huang Z, Fang Y, Wu Z et al (2017) 2017 Consensus and guidelines for the prevention and treatment of adult osteoporosis in Taiwan. Taiwanese Osteoporosis Association, Taipei Huang Z, Fang Y, Wu Z et al (2017) 2017 Consensus and guidelines for the prevention and treatment of adult osteoporosis in Taiwan. Taiwanese Osteoporosis Association, Taipei
17.
go back to reference OSHK Task Group for Formulation of OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong, Ip TP, Cheung SK et al (2013) The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong Med J 19(Suppl 2):1–40 OSHK Task Group for Formulation of OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong, Ip TP, Cheung SK et al (2013) The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong Med J 19(Suppl 2):1–40
18.
go back to reference Singh M, Harinarayan CV, Marwah R, Sahay R, Kalra S, Babhulkar S (2020) Clinical practice guidelines on postmenopausal osteoporosis: an executive summary and recommendations - Update 2019. Indian Menopause Society, Hyderabad Singh M, Harinarayan CV, Marwah R, Sahay R, Kalra S, Babhulkar S (2020) Clinical practice guidelines on postmenopausal osteoporosis: an executive summary and recommendations - Update 2019. Indian Menopause Society, Hyderabad
19.
go back to reference Bhadada SK (2020) Indian Society for Bone and Mineral Research Guidelines 2020. Indian Society for Bone and Mineral Research, New Delhi Bhadada SK (2020) Indian Society for Bone and Mineral Research Guidelines 2020. Indian Society for Bone and Mineral Research, New Delhi
20.
go back to reference Setyohadi B, Hutagalung EUHU, Frederik Adam JM et al (2012) Summary of the Indonesian guidelines for diagnosis and management of osteoporosis. JAFES 27:147CrossRef Setyohadi B, Hutagalung EUHU, Frederik Adam JM et al (2012) Summary of the Indonesian guidelines for diagnosis and management of osteoporosis. JAFES 27:147CrossRef
21.
go back to reference Orimo H (2015) Japanese 2015 guidelines for the prevention and treatment of osteoporosis [in Japanese]. Japan Osteoporosis Society, The Japanese Society for Bone and Mineral Research & Japan Osteoporosis Foundation, Tokyo Orimo H (2015) Japanese 2015 guidelines for the prevention and treatment of osteoporosis [in Japanese]. Japan Osteoporosis Society, The Japanese Society for Bone and Mineral Research & Japan Osteoporosis Foundation, Tokyo
22.
go back to reference Chan SP, Yeap SS, Lee EGM, Chee W, Hew FL, Lee JK, Lim HH, Damodaran P, Mumtaz M (2015) Clinical guidance on management of osteoporosis, 2nd edn. Malaysian Osteoporosis Society, Academy of Medicine & Ministry of Health, Malaysia, Petaling Jaya Chan SP, Yeap SS, Lee EGM, Chee W, Hew FL, Lee JK, Lim HH, Damodaran P, Mumtaz M (2015) Clinical guidance on management of osteoporosis, 2nd edn. Malaysian Osteoporosis Society, Academy of Medicine & Ministry of Health, Malaysia, Petaling Jaya
23.
go back to reference Latt TS, Aye TT, Ko K, Myint T, Hliang NN, Thaung M, Chit TT (2012) Myanmar clinical practice guidelines for osteoporosis. JAFES 27:151–155CrossRef Latt TS, Aye TT, Ko K, Myint T, Hliang NN, Thaung M, Chit TT (2012) Myanmar clinical practice guidelines for osteoporosis. JAFES 27:151–155CrossRef
24.
go back to reference Gilchrist N, Reid IR, Sankaran S, Kim D, Drewry A, Toop L, McClure F (2017) Guidance on the diagnosis and management of osteoporosis in New Zealand. Osteoporosis New Zealand, Wellington Gilchrist N, Reid IR, Sankaran S, Kim D, Drewry A, Toop L, McClure F (2017) Guidance on the diagnosis and management of osteoporosis in New Zealand. Osteoporosis New Zealand, Wellington
25.
go back to reference Li-Yu J, Perez EC, Canete A, Bonifacio L, Llamado LQ, Martinez R, Lanzon A, Sison M, Osteoporosis Society of Philippines Foundation Inc, Philippine Orthopedic Association Clinical Practice Guidelines Task Force Committee on Osteoporosis (2011) Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines. Int J Rheum Dis 14:223–238PubMedCrossRef Li-Yu J, Perez EC, Canete A, Bonifacio L, Llamado LQ, Martinez R, Lanzon A, Sison M, Osteoporosis Society of Philippines Foundation Inc, Philippine Orthopedic Association Clinical Practice Guidelines Task Force Committee on Osteoporosis (2011) Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines. Int J Rheum Dis 14:223–238PubMedCrossRef
26.
go back to reference Chandran M, Ang SB, Au L et al (2018) Appropriate care guide: osteoporosis identification and management in primary care. Ministry of Health, Singapore Chandran M, Ang SB, Au L et al (2018) Appropriate care guide: osteoporosis identification and management in primary care. Ministry of Health, Singapore
27.
go back to reference Yoon HG, Jung HY, Yoon BG (2019) KSBMR physician's guide for osteoporosis [in Korean]. Korean Society for Bone and Mineral Research, Seoul Yoon HG, Jung HY, Yoon BG (2019) KSBMR physician's guide for osteoporosis [in Korean]. Korean Society for Bone and Mineral Research, Seoul
28.
go back to reference Songpatanasilp T, Sritara C, Kittisomprayoonkul W et al (2016) Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis. Osteoporos Sarcopenia 2:191–207PubMedPubMedCentralCrossRef Songpatanasilp T, Sritara C, Kittisomprayoonkul W et al (2016) Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis. Osteoporos Sarcopenia 2:191–207PubMedPubMedCentralCrossRef
29.
go back to reference Vietnam Rheumatology Association (2016) Guidelines for the diagnosis and treatment of osteoporosis [in Vietnamese]. Vietnam Rheumatology Association, Hanoi Vietnam Rheumatology Association (2016) Guidelines for the diagnosis and treatment of osteoporosis [in Vietnamese]. Vietnam Rheumatology Association, Hanoi
31.
go back to reference Koh LK, Sedrine WB, Torralba TP, Kung A, Fujiwara S, Chan SP, Huang QR, Rajatanavin R, Tsai KS, Park HM, Reginster JY, Osteoporosis Self-Assessment Tool for Asians (OSTA) Research Group (2001) A simple tool to identify asian women at increased risk of osteoporosis. Osteoporos Int 12:699–705PubMedCrossRef Koh LK, Sedrine WB, Torralba TP, Kung A, Fujiwara S, Chan SP, Huang QR, Rajatanavin R, Tsai KS, Park HM, Reginster JY, Osteoporosis Self-Assessment Tool for Asians (OSTA) Research Group (2001) A simple tool to identify asian women at increased risk of osteoporosis. Osteoporos Int 12:699–705PubMedCrossRef
32.
go back to reference Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19:1431–1444PubMedCrossRef Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19:1431–1444PubMedCrossRef
34.
go back to reference Pongchaiyakul C, Nguyen ND, Pongchaiyakul C, Nguyen TV (2004) Development and validation of a new clinical risk index for prediction of osteoporosis in Thai women. J Med Assoc Thail 87:910–916 Pongchaiyakul C, Nguyen ND, Pongchaiyakul C, Nguyen TV (2004) Development and validation of a new clinical risk index for prediction of osteoporosis in Thai women. J Med Assoc Thail 87:910–916
35.
go back to reference Shepherd AJ, Cass AR, Carlson CA, Ray L (2007) Development and internal validation of the male osteoporosis risk estimation score. Ann Fam Med 5:540–546PubMedPubMedCentralCrossRef Shepherd AJ, Cass AR, Carlson CA, Ray L (2007) Development and internal validation of the male osteoporosis risk estimation score. Ann Fam Med 5:540–546PubMedPubMedCentralCrossRef
36.
go back to reference Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. Bmj 339:b4229PubMedPubMedCentralCrossRef Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. Bmj 339:b4229PubMedPubMedCentralCrossRef
37.
go back to reference Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. Bmj 344:e3427PubMedCrossRef Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. Bmj 344:e3427PubMedCrossRef
38.
go back to reference Cadarette SM, Jaglal SB, Murray TM (1999) Validation of the simple calculated osteoporosis risk estimation (SCORE) for patient selection for bone densitometry. Osteoporos Int 10:85–90PubMedCrossRef Cadarette SM, Jaglal SB, Murray TM (1999) Validation of the simple calculated osteoporosis risk estimation (SCORE) for patient selection for bone densitometry. Osteoporos Int 10:85–90PubMedCrossRef
39.
go back to reference Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedPubMedCentralCrossRef Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedPubMedCentralCrossRef
40.
go back to reference Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C (2013) Capture the Fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos Int 24:2135–2152PubMedPubMedCentralCrossRef Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C (2013) Capture the Fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos Int 24:2135–2152PubMedPubMedCentralCrossRef
41.
go back to reference Kristensen PK, Rock ND, Christensen HC, Pedersen AB (2020) The Danish Multidisciplinary Hip Fracture Registry 13-year results from a population-based cohort of hip fracture patients. Clin Epidemiol 12:9–21PubMedPubMedCentralCrossRef Kristensen PK, Rock ND, Christensen HC, Pedersen AB (2020) The Danish Multidisciplinary Hip Fracture Registry 13-year results from a population-based cohort of hip fracture patients. Clin Epidemiol 12:9–21PubMedPubMedCentralCrossRef
44.
go back to reference Gjertsen JE, Engesaeter LB, Furnes O, Havelin LI, Steindal K, Vinje T, Fevang JM (2008) The Norwegian Hip Fracture Register: experiences after the first 2 years and 15,576 reported operations. Acta Orthop 79:583–593PubMedCrossRef Gjertsen JE, Engesaeter LB, Furnes O, Havelin LI, Steindal K, Vinje T, Fevang JM (2008) The Norwegian Hip Fracture Register: experiences after the first 2 years and 15,576 reported operations. Acta Orthop 79:583–593PubMedCrossRef
45.
go back to reference Alarcon T, Ojeda-Thies C, Sáez-López P, Gomez-Campelo P, Navarro-Castellanos L, Otero-Puime A, González-Montalvo JI (2020) Usefulness of a national hip fracture registry to evaluate the profile of patients in whom antiosteoporotic treatment is prescribed following hospital discharge. Osteoporos Int 31:1369–1375PubMedCrossRef Alarcon T, Ojeda-Thies C, Sáez-López P, Gomez-Campelo P, Navarro-Castellanos L, Otero-Puime A, González-Montalvo JI (2020) Usefulness of a national hip fracture registry to evaluate the profile of patients in whom antiosteoporotic treatment is prescribed following hospital discharge. Osteoporos Int 31:1369–1375PubMedCrossRef
46.
go back to reference Neuburger J, Currie C, Wakeman R, Tsang C, Plant F, De Stavola B, Cromwell DA, van der Meulen J (2015) The impact of a national clinician-led audit initiative on care and mortality after hip fracture in England: an external evaluation using time trends in non-audit data. Med Care 53:686–691PubMedPubMedCentralCrossRef Neuburger J, Currie C, Wakeman R, Tsang C, Plant F, De Stavola B, Cromwell DA, van der Meulen J (2015) The impact of a national clinician-led audit initiative on care and mortality after hip fracture in England: an external evaluation using time trends in non-audit data. Med Care 53:686–691PubMedPubMedCentralCrossRef
47.
go back to reference Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA (2007) Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Relat Res 461:226–230PubMedCrossRef Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA (2007) Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Relat Res 461:226–230PubMedCrossRef
48.
go back to reference McLellan AR, Reid DM, Forbes K, Reid R, Campbell C, Gregori A, Raby N, Simpson A (2004) Effectiveness of strategies for the secondary prevention of osteoporotic fractures in scotland. CEPS: 99/03. NHS Quality Improvement Scotland, Glasgow McLellan AR, Reid DM, Forbes K, Reid R, Campbell C, Gregori A, Raby N, Simpson A (2004) Effectiveness of strategies for the secondary prevention of osteoporotic fractures in scotland. CEPS: 99/03. NHS Quality Improvement Scotland, Glasgow
49.
go back to reference Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382PubMedCrossRef Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382PubMedCrossRef
50.
go back to reference Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739PubMedCrossRef Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739PubMedCrossRef
51.
go back to reference Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. Jama 301:513–521PubMedCrossRef Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. Jama 301:513–521PubMedCrossRef
52.
go back to reference Chan DD, Chang LY, Akesson KE et al (2018) Consensus on best practice standards for fracture liaison service in the Asia-Pacific region. Arch Osteoporos 13:59PubMedCrossRef Chan DD, Chang LY, Akesson KE et al (2018) Consensus on best practice standards for fracture liaison service in the Asia-Pacific region. Arch Osteoporos 13:59PubMedCrossRef
53.
54.
go back to reference Wu CH, Chen CH, Chen PH, Yang JJ, Chang PC, Huang TC, Bagga S, Sharma Y, Lin RM, Chan DC (2018) Identifying characteristics of an effective fracture liaison service: systematic literature review. Osteoporos Int 29:1023–1047PubMedCrossRef Wu CH, Chen CH, Chen PH, Yang JJ, Chang PC, Huang TC, Bagga S, Sharma Y, Lin RM, Chan DC (2018) Identifying characteristics of an effective fracture liaison service: systematic literature review. Osteoporos Int 29:1023–1047PubMedCrossRef
55.
go back to reference Wu CH, Tu ST, Chang YF, Chan DC, Chien JT, Lin CH, Singh S, Dasari M, Chen JF, Tsai KS (2018) Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. Bone 111:92–100PubMedCrossRef Wu CH, Tu ST, Chang YF, Chan DC, Chien JT, Lin CH, Singh S, Dasari M, Chen JF, Tsai KS (2018) Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. Bone 111:92–100PubMedCrossRef
56.
go back to reference Australian and New Zealand Bone and Mineral Society (2016) Secondary fracture prevention program initiative: resource 1 – secondary fracture prevention program resource pack. Australian and New Zealand Bone and Mineral Society, Sydney Australian and New Zealand Bone and Mineral Society (2016) Secondary fracture prevention program initiative: resource 1 – secondary fracture prevention program resource pack. Australian and New Zealand Bone and Mineral Society, Sydney
57.
go back to reference Wang O, Hu Y, Gong S, Xue Q, Deng Z, Wang L, Liu H, Tang H, Guo X, Chen J, Jia X, Xu Y, Lan L, Lei C, Dong H, Yuan G, Fu Q, Wei Y, Xia W, Xu L (2015) A survey of outcomes and management of patients post fragility fractures in China. Osteoporos Int 26:2631–2640PubMedCrossRef Wang O, Hu Y, Gong S, Xue Q, Deng Z, Wang L, Liu H, Tang H, Guo X, Chen J, Jia X, Xu Y, Lan L, Lei C, Dong H, Yuan G, Fu Q, Wei Y, Xia W, Xu L (2015) A survey of outcomes and management of patients post fragility fractures in China. Osteoporos Int 26:2631–2640PubMedCrossRef
58.
go back to reference Tian M, Gong X, Rath S, Wei J, Yan LL, Lamb SE, Lindley RI, Sherrington C, Willett K, Norton R (2016) Management of hip fractures in older people in Beijing: a retrospective audit and comparison with evidence-based guidelines and practice in the UK. Osteoporos Int 27:677–681PubMedCrossRef Tian M, Gong X, Rath S, Wei J, Yan LL, Lamb SE, Lindley RI, Sherrington C, Willett K, Norton R (2016) Management of hip fractures in older people in Beijing: a retrospective audit and comparison with evidence-based guidelines and practice in the UK. Osteoporos Int 27:677–681PubMedCrossRef
59.
go back to reference Chang LY, Tsai KS, Peng JK, Chen CH, Lin GT, Lin CH, Tu ST, Mao IC, Gau YL, Liu HC, Niu CC, Hsieh MH, Chien JT, Hung WC, Yang RS, Wu CH, Chan DC (2018) The development of Taiwan Fracture Liaison Service network. Osteoporos Sarcopenia 4:47–52PubMedPubMedCentralCrossRef Chang LY, Tsai KS, Peng JK, Chen CH, Lin GT, Lin CH, Tu ST, Mao IC, Gau YL, Liu HC, Niu CC, Hsieh MH, Chien JT, Hung WC, Yang RS, Wu CH, Chan DC (2018) The development of Taiwan Fracture Liaison Service network. Osteoporos Sarcopenia 4:47–52PubMedPubMedCentralCrossRef
60.
go back to reference Leung KS, Yuen WF, Ngai WK, Lam CY, Lau TW, Lee KB, Siu KM, Tang N, Wong SH, Cheung WH (2017) How well are we managing fragility hip fractures? A narrative report on the review with the attempt to setup a Fragility Fracture Registry in Hong Kong. Hong Kong Med J 23:264–271PubMed Leung KS, Yuen WF, Ngai WK, Lam CY, Lau TW, Lee KB, Siu KM, Tang N, Wong SH, Cheung WH (2017) How well are we managing fragility hip fractures? A narrative report on the review with the attempt to setup a Fragility Fracture Registry in Hong Kong. Hong Kong Med J 23:264–271PubMed
61.
go back to reference Chandran M, Tan MZ, Cheen M, Tan SB, Leong M, Lau TC (2013) Secondary prevention of osteoporotic fractures--an “OPTIMAL” model of care from Singapore. Osteoporos Int 24:2809–2817PubMedCrossRef Chandran M, Tan MZ, Cheen M, Tan SB, Leong M, Lau TC (2013) Secondary prevention of osteoporotic fractures--an “OPTIMAL” model of care from Singapore. Osteoporos Int 24:2809–2817PubMedCrossRef
62.
go back to reference Hagino H, Sawaguchi T, Endo N, Ito Y, Nakano T, Watanabe Y (2012) The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int 90:14–21PubMedCrossRef Hagino H, Sawaguchi T, Endo N, Ito Y, Nakano T, Watanabe Y (2012) The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int 90:14–21PubMedCrossRef
63.
go back to reference Baba T, Hagino H, Nonomiya H, Ikuta T, Shoda E, Mogami A, Sawaguchi T, Kaneko K (2015) Inadequate management for secondary fracture prevention in patients with distal radius fracture by trauma surgeons. Osteoporos Int 26:1959–1963PubMedCrossRef Baba T, Hagino H, Nonomiya H, Ikuta T, Shoda E, Mogami A, Sawaguchi T, Kaneko K (2015) Inadequate management for secondary fracture prevention in patients with distal radius fracture by trauma surgeons. Osteoporos Int 26:1959–1963PubMedCrossRef
64.
go back to reference Iba K, Dohke T, Takada J, Sasaki K, Sonoda T, Hanaka M, Miyano S, Yamashita T (2018) Improvement in the rate of inadequate pharmaceutical treatment by orthopaedic surgeons for the prevention of a second fracture over the last 10 years. J Orthop Sci 23:127–131PubMedCrossRef Iba K, Dohke T, Takada J, Sasaki K, Sonoda T, Hanaka M, Miyano S, Yamashita T (2018) Improvement in the rate of inadequate pharmaceutical treatment by orthopaedic surgeons for the prevention of a second fracture over the last 10 years. J Orthop Sci 23:127–131PubMedCrossRef
65.
go back to reference Braatvedt G, Wilkinson S, Scott M, Mitchell P, Harris R (2017) Fragility fractures at Auckland City Hospital: we can do better. Arch Osteoporos 12:64PubMedCrossRef Braatvedt G, Wilkinson S, Scott M, Mitchell P, Harris R (2017) Fragility fractures at Auckland City Hospital: we can do better. Arch Osteoporos 12:64PubMedCrossRef
66.
go back to reference Kim SR, Park YG, Kang SY, Nam KW, Park YG, Ha YC (2014) Undertreatment of osteoporosis following hip fractures in jeju cohort study. J Bone Metab 21:263–268PubMedPubMedCentralCrossRef Kim SR, Park YG, Kang SY, Nam KW, Park YG, Ha YC (2014) Undertreatment of osteoporosis following hip fractures in jeju cohort study. J Bone Metab 21:263–268PubMedPubMedCentralCrossRef
67.
go back to reference Kim SC, Kim MS, Sanfélix-Gimeno G et al (2015) Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med 128:519–526.e511PubMedPubMedCentralCrossRef Kim SC, Kim MS, Sanfélix-Gimeno G et al (2015) Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med 128:519–526.e511PubMedPubMedCentralCrossRef
68.
go back to reference Yu YM, Lee JY, Lee E (2017) Access to anti-osteoporosis medication after hip fracture in Korean elderly patients. Maturitas 103:54–59PubMedCrossRef Yu YM, Lee JY, Lee E (2017) Access to anti-osteoporosis medication after hip fracture in Korean elderly patients. Maturitas 103:54–59PubMedCrossRef
69.
go back to reference Jung Y, Ko Y, Kim HY, Ha YC, Lee YK, Kim TY, Choo DS, Jang S (2019) Gender differences in anti-osteoporosis drug treatment after osteoporotic fractures. J Bone Miner Metab 37:134–141PubMedCrossRef Jung Y, Ko Y, Kim HY, Ha YC, Lee YK, Kim TY, Choo DS, Jang S (2019) Gender differences in anti-osteoporosis drug treatment after osteoporotic fractures. J Bone Miner Metab 37:134–141PubMedCrossRef
70.
go back to reference Angthong C, Rodjanawijitkul S, Samart S, Angthong W (2013) Prevalence of bone mineral density testing and osteoporosis management following low- and high-energy fractures. Acta Orthop Traumatol Turc 47:318–322PubMedCrossRef Angthong C, Rodjanawijitkul S, Samart S, Angthong W (2013) Prevalence of bone mineral density testing and osteoporosis management following low- and high-energy fractures. Acta Orthop Traumatol Turc 47:318–322PubMedCrossRef
71.
go back to reference Ebeling PR, Chan DC, Lau TC, Lee JK, Songpatanasilp T, Wong SH, Hew FL, Sethi R, Williams M (2020) Secondary prevention of fragility fractures in Asia Pacific: an educational initiative. Osteoporos Int 31:805–826PubMedCrossRef Ebeling PR, Chan DC, Lau TC, Lee JK, Songpatanasilp T, Wong SH, Hew FL, Sethi R, Williams M (2020) Secondary prevention of fragility fractures in Asia Pacific: an educational initiative. Osteoporos Int 31:805–826PubMedCrossRef
72.
go back to reference Johnell O, Oden A, Caulin F, Kanis JA (2001) Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int 12:207–214PubMedCrossRef Johnell O, Oden A, Caulin F, Kanis JA (2001) Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int 12:207–214PubMedCrossRef
73.
go back to reference Nymark T, Lauritsen JM, Ovesen O, Röck ND, Jeune B (2006) Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. Osteoporos Int 17:1353–1357PubMedCrossRef Nymark T, Lauritsen JM, Ovesen O, Röck ND, Jeune B (2006) Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. Osteoporos Int 17:1353–1357PubMedCrossRef
74.
go back to reference Giangregorio LM, Leslie WD (2010) Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res 25:1400–1405PubMedCrossRef Giangregorio LM, Leslie WD (2010) Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res 25:1400–1405PubMedCrossRef
76.
go back to reference Johansson H, Siggeirsdóttir K, Harvey NC, Odén A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775–780PubMedCrossRef Johansson H, Siggeirsdóttir K, Harvey NC, Odén A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775–780PubMedCrossRef
77.
go back to reference Bonafede M, Shi N, Barron R, Li X, Crittenden DB, Chandler D (2016) Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. Arch Osteoporos 11:26PubMedPubMedCentralCrossRef Bonafede M, Shi N, Barron R, Li X, Crittenden DB, Chandler D (2016) Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. Arch Osteoporos 11:26PubMedPubMedCentralCrossRef
78.
go back to reference Deloumeau A, Moltó A, Roux C, Briot K (2017) Determinants of short term fracture risk in patients with a recent history of low-trauma non-vertebral fracture. Bone 105:287–291PubMedCrossRef Deloumeau A, Moltó A, Roux C, Briot K (2017) Determinants of short term fracture risk in patients with a recent history of low-trauma non-vertebral fracture. Bone 105:287–291PubMedCrossRef
79.
go back to reference Kanis JA, Johansson H, Odén A, Harvey NC, Gudnason V, Sanders KM, Sigurdsson G, Siggeirsdottir K, Fitzpatrick LA, Borgström F, McCloskey EV (2018) Characteristics of recurrent fractures. Osteoporos Int 29:1747–1757PubMedPubMedCentralCrossRef Kanis JA, Johansson H, Odén A, Harvey NC, Gudnason V, Sanders KM, Sigurdsson G, Siggeirsdottir K, Fitzpatrick LA, Borgström F, McCloskey EV (2018) Characteristics of recurrent fractures. Osteoporos Int 29:1747–1757PubMedPubMedCentralCrossRef
80.
go back to reference Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster JY (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1–12PubMedCrossRef Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster JY (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1–12PubMedCrossRef
81.
go back to reference Kanis J, Johansson H, Harvey N, Gudnason V, Sigurdsson G, Siggeirsdóttir K, Lorentzon M, Liu E, Vandenput L, McCloskey E (2020) Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. Osteoporos Int 31:1817–1828PubMedPubMedCentralCrossRef Kanis J, Johansson H, Harvey N, Gudnason V, Sigurdsson G, Siggeirsdóttir K, Lorentzon M, Liu E, Vandenput L, McCloskey E (2020) Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. Osteoporos Int 31:1817–1828PubMedPubMedCentralCrossRef
82.
go back to reference Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB (2020) American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis – 2020 update. Endocr Pract 26:1–46PubMedCrossRef Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB (2020) American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis – 2020 update. Endocr Pract 26:1–46PubMedCrossRef
83.
go back to reference Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230–240PubMedCrossRef Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230–240PubMedCrossRef
84.
go back to reference Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427PubMedCrossRef Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427PubMedCrossRef
85.
go back to reference Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751PubMedCrossRef Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751PubMedCrossRef
86.
go back to reference Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP, for the Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785–3793PubMedPubMedCentralCrossRef Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP, for the Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785–3793PubMedPubMedCentralCrossRef
87.
go back to reference Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey E, EUROFORS Investigators (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852–860PubMedCrossRef Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey E, EUROFORS Investigators (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852–860PubMedCrossRef
88.
go back to reference Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147–1155PubMedPubMedCentralCrossRef Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147–1155PubMedPubMedCentralCrossRef
89.
go back to reference Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543PubMedCrossRef Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543PubMedCrossRef
90.
go back to reference Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers B, Reginster JY, Silverman S, Wyers CE, Boonen A (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics 33:205–224PubMedCrossRef Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers B, Reginster JY, Silverman S, Wyers CE, Boonen A (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics 33:205–224PubMedCrossRef
91.
go back to reference Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408PubMedCrossRef Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408PubMedCrossRef
92.
go back to reference Lippuner K, Johansson H, Borgström F, Kanis JA, Rizzoli R (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos Int 23:2579–2589PubMedCrossRef Lippuner K, Johansson H, Borgström F, Kanis JA, Rizzoli R (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos Int 23:2579–2589PubMedCrossRef
93.
go back to reference McCloskey E, Kanis JA, Johansson H, Harvey N, Odén A, Cooper A, Cooper C, Francis RM, Reid DM, Marsh D, Selby P, Thompson F, Hewitt S, Compston J (2015) FRAX-based assessment and intervention thresholds – an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int 26:2091–2099PubMedCrossRef McCloskey E, Kanis JA, Johansson H, Harvey N, Odén A, Cooper A, Cooper C, Francis RM, Reid DM, Marsh D, Selby P, Thompson F, Hewitt S, Compston J (2015) FRAX-based assessment and intervention thresholds – an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int 26:2091–2099PubMedCrossRef
94.
go back to reference Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY (2020) Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: a US payer perspective. Semin Arthritis Rheum 50:394–400PubMedCrossRef Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY (2020) Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: a US payer perspective. Semin Arthritis Rheum 50:394–400PubMedCrossRef
96.
go back to reference Cui L, He T, Jiang Y, Li M, Wang O, Jiajue R, Chi Y, Xu Q, Xing X, Xia W (2020) Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data. Osteoporos Int 31:307–316PubMedCrossRef Cui L, He T, Jiang Y, Li M, Wang O, Jiajue R, Chi Y, Xu Q, Xing X, Xia W (2020) Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data. Osteoporos Int 31:307–316PubMedCrossRef
97.
go back to reference Li N, Zheng B, Liu M, Zhou H, Zhao L, Cai H, Huang J (2019) Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China. Menopause 26:906–914PubMedCrossRef Li N, Zheng B, Liu M, Zhou H, Zhao L, Cai H, Huang J (2019) Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China. Menopause 26:906–914PubMedCrossRef
98.
go back to reference Yoshizawa T, Nishino T, Okubo I, Yamazaki M (2018) Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate. Arch Osteoporos 13:94PubMedCrossRef Yoshizawa T, Nishino T, Okubo I, Yamazaki M (2018) Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate. Arch Osteoporos 13:94PubMedCrossRef
99.
go back to reference Moriwaki K, Mouri M, Hagino H (2017) Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporos Int 28:1939–1950PubMedPubMedCentralCrossRef Moriwaki K, Mouri M, Hagino H (2017) Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporos Int 28:1939–1950PubMedPubMedCentralCrossRef
100.
go back to reference Karnon J, Shafie AS, Orji N, Usman SK (2016) What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia. Cost Eff Resour Alloc 14:11PubMedPubMedCentralCrossRef Karnon J, Shafie AS, Orji N, Usman SK (2016) What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia. Cost Eff Resour Alloc 14:11PubMedPubMedCentralCrossRef
Metadata
Title
Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region
Authors
M. Chandran
P. J. Mitchell
T. Amphansap
S. K. Bhadada
M. Chadha
D.-C. Chan
Y.-S. Chung
P. Ebeling
N. Gilchrist
A. Habib Khan
P. Halbout
F. L. Hew
H.-P. T. Lan
T. C. Lau
J. K. Lee
S. Lekamwasam
G. Lyubomirsky
L. B. Mercado-Asis
A. Mithal
T. V. Nguyen
D. Pandey
I. R. Reid
A. Suzuki
T. T. Chit
K. L. Tiu
T. Valleenukul
C. K. Yung
Y. L. Zhao
on behalf of the Asia Pacific Consortium on Osteoporosis (APCO)
Publication date
01-07-2021
Publisher
Springer London
Published in
Osteoporosis International / Issue 7/2021
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-020-05742-0

Other articles of this Issue 7/2021

Osteoporosis International 7/2021 Go to the issue